Canadian Manufacturing

Frontier Lithium hires new VP of Technology

Most recently Dr. Cao was Chief Technology Officer for a subsidiary of CATL, where he participated in all aspects of lithium mining and concentrate production.

February 22, 2021  by CM Staff

SUDBURY — Frontier Lithium Inc. announces the hiring of Dr. Naizhen Cao as Vice President Technology. Dr. Cao is an industry veteran having worked both in China and Canada as senior technical leader with experience in lithium and battery materials. During his career, he held several key positions within the lithium industry including: Chief Scientist at Tianqi Lithium, a global lithium producer, where he managed the Technical Division and established the Key Lab of Lithium resources and lithium materials of the Sichuan Province of China. In addition, Dr. Cao launched and led key project on lithium materials production. Most recently Dr. Cao was Chief Technology Officer for a subsidiary of CATL, where he participated in all aspects of lithium mining and concentrate production. Mr. Cao published more than 50 scientific papers and filed more than 60 patents with particular proficiency in battery materials with specific focus on lithium chemicals and metal/alloys. Dr. Cao holds a Ph.D., from Tsinghua University, China, in Materials Science and engineering and held a Postdoc at Laval University, Canada in Chemical Engineering.

“Dr. Cao will be assuming the new role of VP Technology at Frontier Lithium as we grow and transition from an exploration company towards development of lithium chemicals from the Great Lakes region of North America.” commented Trevor Walker, President & CEO of Frontier Lithium. “Dr. Cao brings a rare combination of technical and operational skill sets that perfectly suits our current and future stages of development. He will be working closely with our technology partners on our patent pending process which is currently being piloted, as well future demonstration and commercialization stages. We have built very strong technical partnerships and now with the addition of Dr. Cao we are significantly de-risking our project execution with the goal of producing premium chemicals.”

The Company also announces that pursuant to its “Stock Option Plan” it has re-established 6,813,334 stock options, previously cancelled on September 9, 2020, to certain employees, officers, directors and strategic advisors. The options are set for a period of five years, expiring on February 23, 2026. The options are priced at $1.05 and are subject to regulatory approval.

Advertisment